Clinical Research Directory
Browse clinical research sites, groups, and studies.
Study of BHV-1400 in IgA Nephropathy
Sponsor: Biohaven Therapeutics Ltd.
Summary
The purpose of this study is to determine if BHV-1400 is a safe and tolerable treatment in participants with IgA Nephropathy (IgAN).
Official title: An Open-Label Biomarker Study of BHV-1400 in IgA Nephropathy
Key Details
Gender
All
Age Range
18 Years - 65 Years
Study Type
INTERVENTIONAL
Enrollment
20
Start Date
2025-07-30
Completion Date
2027-07
Last Updated
2026-03-10
Healthy Volunteers
No
Conditions
Interventions
BHV-1400
BHV-1400 is delivered subcutaneously (SC)
Locations (12)
Site-001
Farmington, Connecticut, United States
Site-003
Miami Lakes, Florida, United States
Site-011
Miami Lakes, Florida, United States
Site-013
Orlando, Florida, United States
Site-005
Pembroke Pines, Florida, United States
Site-008
Lawrenceville, Georgia, United States
Site-009
Hinsdale, Illinois, United States
Site-012
Indianapolis, Indiana, United States
Site-006
Chesterfield, Missouri, United States
Site-002
Dakota Dunes, South Dakota, United States
Site-004
Houston, Texas, United States
Site-007
Leicester, United Kingdom